HIV-Infected Women with Low-Grade Squamous Intraepithelial Lesion on Cervical Cytology Have Higher Risk of Underlying High-Grade Cervical Intraepithelial Neoplasia

Nawin Sakdadech, Tanarat Muangmool, Jatupol Srisomboon, Nawin Sakdadech, Tanarat Muangmool, Jatupol Srisomboon

Abstract

Objective: To evaluate the risk of histological high-grade cervical lesions defined as cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women with human immunodeficiency virus (HIV) infection who had low-grade squamous intraepithelial lesions (LSIL) on cervical cytological screening compared with HIV-uninfected women who had similar cytology.

Methods: 127 HIV-positive women aged 18-65 years with LSIL cytology undergoing colposcopic examination between January 2008 and December 2019 at Chiang Mai University Hospital were reviewed. By matching 1:1 ratio for age (±5 years) and examination time period (±12 months), 127 HIV-negative women with LSIL cytology in the same period were recruited as controlled subjects for comparison. The patients' characteristics, HIV status, CD4 counts, antiretroviral therapy, and histopathology on cervical biopsy were analyzed.

Results: HIV-infected women significantly had early sexual debut (age < 20 years) and more sexual partners (≥2) than HIV-uninfected women. The risk of underlying CIN2+ in HIV-infected women was significantly higher than that in HIV-negative women (20.5% vs. 9.4%, p = 0.021) with an odds ratio (OR) of 2.47 and 95% confidence interval (CI) = 1.18-5.14. After adjustment, the risk of underlying CIN2+ in HIV-infected women remained significantly higher than that in HIV-uninfected women (adjusted OR = 2.55, 95% CI = 1.11-5.82, p = 0.027).

Conclusion: Among women with LSIL on cervical cytology, the risk of underlying CIN2+ in HIV-infected women was approximately 2.5 times higher than those without HIV infection. Colposcopy is indicated particularly in the case of women with a long duration of HIV infection.

Keywords: HIV; LSIL; cervical cytology; cervical screening result; uterine cervix.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492.
    1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999;189:12–19. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>;2-F.
    1. Duerr A., Kieke B., Warren D., Shah K., Burk R., Peipert J.F., Schuman P., Klein R.S. Human papillomavirus-associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus. Am. J. Obstet. Gynecol. 2001;184:584–590. doi: 10.1067/mob.2001.111791.
    1. Mapanga W., Girdler-Brown B., Feresu S.A., Chipato T., Singh E. Prevention of cervical cancer in HIV-seropositive women from developing countries through cervical cancer screening: A systematic review. Syst. Rev. 2018;7:198. doi: 10.1186/s13643-018-0874-7.
    1. Massad L.S., Xie X., D’Souza G., Darragh T.M., Minkoff H., Wright R., Colie C., Sanchez-Keeland L., Strickler H.D. Incidence of cervical precancers among HIV seropositive women. Am. J. Obstet. Gynecol. 2015;212:606.e1–606.e8. doi: 10.1016/j.ajog.2014.12.003.
    1. Kietpeerakool C., Tangjitgamol S., Srisomboon J. Histopathological outcomes of women with abnormal cervical cytology: A review of literature in Thailand. Asian Pac. J. Cancer Prev. 2014;15:6489–6494. doi: 10.7314/APJCP.2014.15.16.6489.
    1. Six C., Heard I., Bergeron C., Orth G., Poveda J.D., Zagury P., Cesbron P., Crenn-Hebert C., Pradinaud R., Sobesky M., et al. Comparative prevalence, incidence and short-term prognosis of cervical squamous intraepithelial lesions amongst HIV-positive and HIV-negative women. AIDS. 1998;12:1047–1056. doi: 10.1097/00002030-199809000-00013.
    1. Wright T.C., Jr., Cox J.T., Massad L.S., Twiggs L.B., Wilkinson E.J. 2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. J. Low Genit. Tract. Dis. 2002;6:127–143. doi: 10.1097/00128360-200204000-00012.
    1. Suwankanta N., Kietpeerakool C., Srisomboon J., Khunamornpong S., Siriaunkgul S. Underlying histopathology of HIV-infected women with squamous cell abnormalities on cervical cytology. Asian Pac. J. Cancer Prev. 2008;9:441–444.
    1. Manamela P.K., Kgomo K.A., van Gelderen C.J., Lekha A.R., Michelow P., van den Berg E.J., Adam Y. Low-grade squamous intraepithelial lesions among women with HIV. Int. J. Gynaecol. Obstet. 2018;142:78–83. doi: 10.1002/ijgo.12505.
    1. Fruchter R.G., Maiman M., Sillman F.H., Camilien L., Webber C.A., Kim D.S. Characteristics of cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus. Am. J. Obstet. Gynecol. 1994;171:531–537. doi: 10.1016/0002-9378(94)90294-1.
    1. Wright T.C., Jr., Moscarelli R.D., Dole P., Ellerbrock T.V., Chiasson M.A., Van Devanter N. Significance of mild cytologic atypia in women infected with human immunodeficiency virus. Obstet. Gynecol. 1996;87:515–519. doi: 10.1016/0029-7844(95)00472-6.
    1. Boardman L.A., Cotter K., Raker C., Cu-Uvin S. Cervical intraepithelial neoplasia grade 2 or worse in human immunodeficiency virus-infected women with mildly abnormal cervical cytology. Obstet. Gynecol. 2008;112:238–243. doi: 10.1097/01.AOG.0000320309.34046.89.
    1. Anderson J.R., Paramsothy P., Heilig C., Jamieson D.J., Shah K., Duerr A., Group H.I.V.E.R.S. Accuracy of Papanicolaou test among HIV-infected women. Clin. Infect. Dis. 2006;42:562–568. doi: 10.1086/499357.
    1. Massad L.S., Collins Y.C., Meyer P.M. Biopsy correlates of abnormal cervical cytology classified using the Bethesda system. Gynecol. Oncol. 2001;82:516–522. doi: 10.1006/gyno.2001.6323.
    1. Fairman A., Tan J., Quinn M. Women with low-grade abnormalities on Pap smear should be referred for colposcopy. Aust. N. Z. J. Obstet. Gynaecol. 2004;44:252–255. doi: 10.1111/j.1479-828X.2004.00223.x.
    1. Chute D.J., Covell J., Pambuccian S.E., Stelow E.B. Cytologic-histologic correlation of screening and diagnostic Papanicolaou tests. Diagn. Cytopathol. 2006;34:503–506. doi: 10.1002/dc.20462.
    1. Saayman F., Gelderen C.J.V., Michelow P., Berg E.J.V.D., Adam Y. Effect of 2 referral intervals on diagnostic discordance between cytology and histology at a colposcopy clinic. Int. J. Gynaecol. Obstet. 2013;120:257–261. doi: 10.1016/j.ijgo.2012.09.022.
    1. Kelly H., Weiss H.A., Benavente Y., de Sanjose S., Mayaud P. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: A systematic review and meta-analysis. Lancet HIV. 2018;5:e45–e58. doi: 10.1016/S2352-3018(17)30149-2.
    1. Clark R., Hagensee M. Human papilloma virus infections and disease in HIV. HIV Clin. 2009;21:3–5.
    1. Brito M.J., Sequeira P., Silva I., Quintas A., Martins C., Felix A. CD4(+) and CD8(+) cell populations in HIV-positive women with cervical squamous intra-epithelial lesions and squamous cell carcinoma. Int. J. Infect. Dis. 2020;103:370–377. doi: 10.1016/j.ijid.2020.10.083.
    1. Zhang D.Y., Chen W., Zhang H.Y., Lv S.Q., Lu X.N., Tao Y.P., Zhang M., Liu J.F., Yang M., Qiao Y.L., et al. Cervical neoplastic lesions in relation to CD4 T-lymphocyte counts and antiretroviral therapy among women with clinical stage 1 HIV in Yunnan, China. Kaohsiung J. Med. Sci. 2020;36:450–459. doi: 10.1002/kjm2.12175.
    1. Phillips A.N., Dunn D., Sabin C., Pozniak A., Matthias R., Geretti A.M., Clarke J., Churchill D., Williams I., Hill T., et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 2005;19:487–494. doi: 10.1097/01.aids.0000162337.58557.3d.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi